Keros Therapeutics Inc (KROS)

SG&A Expenses

$40.62M

TTM · Period ending: · USD

KROS logo

KROS SG&A Expenses

Latest reported$40.62M
KROS TTM SG&A Expenses ($3.18M → $40.62M)
High-resolution chart · PNG

KROS sg&a expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Keros Therapeutics Inc SG&A Expenses — Trailing twelve months (TTM) (USD)
Period endingSG&A Expenses (USD)
40,623,000
46,499,000
46,849,000
45,771,000
45,464,000
40,943,000
40,754,000
39,194,000
37,971,000
36,813,000
34,283,000
32,271,000
30,611,000
29,255,000
27,525,000
26,163,000
24,591,000
22,802,000
21,028,000
18,914,000
17,102,000
15,094,000
12,797,000
10,247,000
7,666,000
4,670,000
3,184,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.